Patents Assigned to Prokarium Limited
  • Cancer therapy
    Patent number: 12214001
    Abstract: The present invention relates to the field of cancer therapy. In particular, the present invention relates to a live attenuated Gram-negative bacterium for use in the treatment, reduction, inhibition or control of a neoplastic disease in a subject undergoing or intended to undergo immunotherapy with a checkpoint inhibitor therapy, an adoptive T cell therapy and/or an allogeneic or an autologous CAR-T therapy simultaneously, separately or sequentially with the administration of the live attenuated Gram-negative bacterium.
    Type: Grant
    Filed: December 6, 2022
    Date of Patent: February 4, 2025
    Assignee: Prokarium Limited
    Inventors: Livija Deban, Hyam Levitsky
  • Cancer therapy with live attenuated bacteria
    Patent number: 12171791
    Abstract: The present invention relates to the field of cancer therapy. In particular, the present invention relates to a first composition comprising a live attenuated bacterium for use in the treatment, prevention, reduction, inhibition, prevention of recurrence, or control of a neoplastic disease in a subject being or intended to be administered a second composition comprising a live attenuated bacterium, said bacterium being the same or different to that of the first composition and methods thereof.
    Type: Grant
    Filed: July 28, 2022
    Date of Patent: December 24, 2024
    Assignee: Prokarium Limited
    Inventors: Livija Deban, Nicholas Glanville
  • Cancer therapy
    Patent number: 12121551
    Abstract: The present invention relates to the field of cancer therapy. In particular, the present invention relates to a live attenuated Gram-negative bacterium for use in the treatment, reduction, inhibition or control of a neoplastic disease in a subject undergoing or intended to undergo immunotherapy with a checkpoint inhibitor therapy, an adoptive T cell therapy and/or an allogeneic or an autologous CAR-T therapy simultaneously, separately or sequentially with the administration of the live attenuated Gram-negative bacterium.
    Type: Grant
    Filed: May 24, 2022
    Date of Patent: October 22, 2024
    Assignee: Prokarium Limited
    Inventors: Livija Deban, Hyam Levitsky
  • Cancer therapy
    Patent number: 11529378
    Abstract: The present invention relates to the field of cancer therapy. In particular, the present invention relates to a live attenuated Gram-negative bacterium for use in the treatment, reduction, inhibition or control of a neoplastic disease in a subject undergoing or intended to undergo immunotherapy with a checkpoint inhibitor therapy, an adoptive T cell therapy and/or an allogeneic or an autologous CAR-T therapy simultaneously, separately or sequentially with the administration of the live attenuated Gram-negative bacterium.
    Type: Grant
    Filed: June 10, 2021
    Date of Patent: December 20, 2022
    Assignee: PROKARIUM LIMITED
    Inventors: Livija Deban, Hyam Levitsky
  • Modified strain of Typhi
    Patent number: 10806778
    Abstract: The present invention relates to the modification of a live attenuated strain of Salmonella enterica serovar Typhi, wherein its natural surface-exposed polysaccharide and flagellin antigens may be converted to, or augmented by, those from other strains of Salmonella, including S. enterica serovars Paratyphi, Typhimurium and Enteritidis. The present invention also relates to modified strains of Salmonella enterica serovar Typhi being suitable for use as components of a vaccine for enteric fever and salmonellosis.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: October 20, 2020
    Assignee: PROKARIUM LIMITED
    Inventors: Rocky Marc Cranenburgh, Annelise Juliette Soulier
  • Formulations of viable cells for oral delivery
    Patent number: 10016467
    Abstract: This invention relates to solid formulations for the oral delivery of live microbial cells which comprise dried viable cells and small amounts of a bile acid binding agent, for example, an anion exchange resin such as cholestyramine. The presence of bile acid binding agents in the formulation significantly increases the survival of the cells in the intestinal tract and facilitates delivery of the viable cells to the intestine.
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: July 10, 2018
    Assignees: Cambridge Enterprise Limited, Prokarium Limited
    Inventors: Alexander Edwards, Nigel Slater